RT Journal Article
SR Electronic
T1 Predictors of symptomatic laboratory-confirmed SARS-COV-2 reinfection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.28.20203190
DO 10.1101/2020.09.28.20203190
A1 Murillo-Zamora, Efrén
A1 Hernandez-Suarez, Carlos M.
A1 Lugo-Radillo, Agustin
A1 Aguilar-Sollano, Felipe
A1 Mendoza-Cano, Oliver
YR 2020
UL http://medrxiv.org/content/early/2020/09/29/2020.09.28.20203190.abstract
AB Objective To identify factors predicting symptomatic laboratory-positive SARS-COV-2 reinfection.Method We conducted a nationwide retrospective cohort study and data from 99,993 confirmed cases of COVID-19 were analyzed.Results The overall risk of reinfection (28 or more elapsed days between both episodes onset) was 0.21%, and older subjects and those with mild primary disease were at reduced risk of reinfection. Healthcare workers and immunosuppressed or renal patients had at greater risk of SARS-COV-2 reinfection.Conclusions If replicated in other populations, these results may be useful to prioritize efforts focusing on the reduction of SARS-COV-2 spread and the related burden.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was self-funded by the researchers.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Health Research Committee 601 of the Mexican Institute of Social Security provided approval (R-2020-601-015). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analyzed during this study are included in this published article.